Skip to content

The effect of fenofibrate on the prevention of neonatal hyperbilirubinemia in mothers with O type blood group

The effect of fenofibrate on the prevention of neonatal hyperbilirubinemia in mothers with O type blood group

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200822048473N1
Enrollment
120
Registered
2020-08-24
Start date
2020-08-24
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal jaundice. Neonatal jaundice due to other excessive hemolysis

Interventions

Intervention 1: Intervention group: Fenofibrate is given as a single dose of 10 mg per kg. Intervention 2: Control group: No medicine is given.

Sponsors

Babol University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 28 Days

Inclusion criteria

Inclusion criteria: Term neonatal (37 weeks to 41 weeks and 6 days) Neonatal with blood type A or B from mothers with positive O blood type and fathers with A, B or AB blood types Without congenital anomalies, birth trauma and history of resuscitation at birth Neonatal born by elective cesarean section who did not receive induction before delivery Rh incompatibility

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Transcutaneous bilirubin level. Timepoint: Measurement of transcutaneous bilirubin levels at the end of 12, 24, 48 and 72 hours after birth and at the time of admission, in both control and fenofibrate groups. Method of measurement: Transcutaneous bilirubin meter.

Secondary

MeasureTime frame
Jaundice leading to hospitalization. Timepoint: During hospitalization. Method of measurement: Blood test.;Duration of phototherapy. Timepoint: During hospitalization. Method of measurement: Duration in days.;The rate of severe jaundice. Timepoint: During hospitalization. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeddighe Norouzian

Babol University of Medical Sciences

norouzian88s@gmail.com+98 11 3219 2832

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026